## Assessing the risk stratification of breast cancer polygenic risk scores in two Brazilian samples

Barreiro, R.A.S<sup>1,2</sup>, Almeida, TF<sup>1</sup>, Gomes, CS<sup>1,3</sup>, Monfardini, F<sup>1</sup>, Farias, AA<sup>1</sup>, Tunes, GC<sup>1</sup>, Souza, GM<sup>1</sup>, Duim, E<sup>1</sup>, Correia, JS<sup>1</sup>, Coelho, AVC<sup>1</sup>, Caraciolo, MP<sup>1</sup>, Duarte, YAO<sup>4,5</sup>, Zatz, M<sup>6,7</sup>, Amaro, E<sup>1</sup>, Oliveira, JB<sup>1</sup>, Bitarello, BD<sup>8</sup>, Brentani, H<sup>3</sup>, Naslavsky, MS<sup>1,6,7</sup>.

## **ABSTRACT**

Polygenic risk scores (PRS) for breast cancer (BC) have a clear clinical utility in risk prediction. PRS transferability across populations and ancestry groups is hampered by population-specific factors, ultimately leading to differences in variant effects, such as linkage disequilibrium (LD) and differences in variant frequency (AF-diff). Thus, locally-sourced population-based phenotypic and genomic datasets are essential to assess the validity of PRS derived from signals detected across populations. Here, assess the transferability of a BC PRS composed of 313 risk variants (313-PRS) in two Brazilian tri-hybrid admixed ancestries (European, African and Native American) whole-genome sequenced cohorts. We computed 313-PRS in both cohorts (n=753 and n=853) versus the UK Biobank (UKBB, n=264,307) as reference. We show that although the Brazilian cohorts have a high European (EA) component, with AF-diff and to a lesser extent LD patterns like those found in EA populations, the 313-PRS distribution is inflated when compared to that of the UKBB, leading to potential overestimation of PRS-based risk if EA is taken as a standard. Interestingly, we find that case-controls lead to equivalent predictive power when compared to UKBB-EA samples with AUROC values of 0.66-0.62

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. compared to 0.63 for UKBB.

<sup>&</sup>lt;sup>1</sup>Hospital Israelita Albert Einstein, São Paulo, SP, Brazil

<sup>&</sup>lt;sup>2</sup>Universidade de São Paulo, Departamento de Bioquímica, São Paulo, SP, Brazil

<sup>&</sup>lt;sup>3</sup>Institute of Psychiatry, University of Sao Paulo, Medical School, São Paulo, SP, Brazil

<sup>&</sup>lt;sup>4</sup>Medical-Surgical Nursing Department, School of Nursing, University of São Paulo, SP, Brazil

<sup>&</sup>lt;sup>5</sup>Epidemiology Department, Public Health School, University of São Paulo, São Paulo, SP, Brazil

<sup>&</sup>lt;sup>6</sup>Human Genome and Stem Cell Research Center, University of São Paulo, São Paulo, SP, Brazil;

<sup>&</sup>lt;sup>7</sup>Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo, São Paulo, SP, Brazil

<sup>&</sup>lt;sup>8</sup>Biology Department, Bryn Mawr College, 101 N. Merion Avenue, Bryn Mawr, PA 19010-2899

INTRODUCTION

Assessing polygenic risk scores (PRS) transferability across ancestries is crucial if genetic risk

stratification at the clinical level is to be implemented in populations with ancestry profiles that

differ from those assessed in genome-wide association studies (GWAS) 1. PRS derived by

using individuals from a given genetic ancestry yield reduced predictions when tested in

individuals of other ancestries, including those with admixed genomes, due to a complex

interaction between differences in linkage disequilibrium (LD) and allele frequencies (AF)

among populations, as well as population specific gene-environment and epistatic effects - all

of which contribute to each disease or trait's genetic architecture. The consequences of

different populations having these population-specific parameters ultimately lead to differences

in variant effects, and overall PRS performance. To address this issue, novel statistical genetic

techniques are being applied <sup>2,3</sup> and diverse new genetic databases are becoming available

<sup>4,5</sup>. Moreover, improvements to this performance discrepancy outside of the tested ancestry

have been proposed <sup>6</sup> and a few studies have focused on admixed cohorts <sup>3,7</sup>, but none

provided a definitive solution.

The potential use of PRS for improvements in disease prevention and management has been

a prolific area of scientific investigation in the past decade, enabled by the availability of large

datasets such as the UK BioBank (UKBB). While an essential resource, the UKBB and other

major Biobanks are heavily biased in their ancestry representation <sup>1,3,8</sup>. Thus, much of the

aforementioned assessments of transferability of PRS across ancestries rely on smaller

cohorts that contain a majority of underrepresented ancestry groups such as

Latino/Latinx/Hispanic, African/Black/African-American, Native American, and East Asian.

As cohorts of over 1,000 admixed individuals with comprehensive phenotypic characterization

and high-coverage whole-genome sequencing (WGS) data arise in Brazil 4,5, evaluating the

distribution of PRS derived from large European GWAS becomes an important first step prior

to clinical implementation. Breast cancer (BC) is the worldwide leading cause of death in

women and a complex disorder of multifactorial inheritance. While up to 10% of BC cases are

attributed to large effect pathogenic variants segregating in families, most affected individuals

are not carriers, suggesting that sporadic occurrence is influenced by a polygenic combination

of small to moderate effect variants <sup>1</sup> with familial aggregation and heritability reaching 55% <sup>9</sup>.

For BC, PRS derived from European ancestry (EA) individuals do have predictive ability even

in African ancestry (AA) populations, but performance dropped significantly compared to the

EA population <sup>10</sup>. A 313-SNP BC PRS ("313-PRS") trained in EA populations was shown to

have improved predictive power compared to previously described breast cancer PRS 11.

Moreover, the 313-PRS has greater discriminatory power compared to risk prediction models

based only on classical risk factors in EA populations and its incorporation in BC predictive

models provide a greater level of risk stratification in the general population 12. Thus, "risk-

stratified" breast cancer screening could potentially contribute to breast cancer early detection

and the 313-PRS have been proposed as a useful tool to improve screening efficiency <sup>13</sup>.

Here, we investigate the potential for the 313-PRS <sup>11</sup> as a screening tool for BC in two Brazilian

admixed cohorts. We compare the PRS distributions between these Brazilian cohorts and the

UKBB (composed largely of EA individuals) and evaluate the predictive power of a model

including 313-PRS as predictor. We find that even though the Brazilian cohorts have a

relatively high EA component mirrorer by both LD and AF-diff, the overall PRS distribution was

inflated when compared to the UKBB, leading to potential overestimation of PRS-based risk if

these cohorts are assumed to have similar PRS distributions as the UKBB. Nevertheless,

stratification by outcomes led to an equivalent area under the receiver operator curve (AUROC)

values when compared to UKBB. We discuss the limitations and implications of these findings

below.

**MATERIALS & METHODS** 

Genotypic and phenotypic data. Data for the present study comes from female samples of

two Brazilian cohorts: 1) The Health, Well-being and Aging Study (SABE, acronym in

Portuguese), a census-based sample of individuals aged above 60 years old living in São

Paulo, Brazil, with 21 cases of BC and 732 controls<sup>5</sup>; 2) The Rare Genomes Project (GRAR)<sup>4</sup>

, a nationwide sample of probands ascertained by being at risk for Mendelian disorders

recruited after clinical evaluation, comprising 322 cases of BC and 531 controls. To address

potential confounders in GRAR, we removed individuals with related cancers such as ovarian

and pancreatic cancer and BC-cases with causative monogenic variants. We also used the

UKBB imputed dataset <sup>14</sup> (Project 74348), with 11,245 cases and 253,062 controls for

comparison. See **Supplementary Methods** for details.

**Data processing.** We mapped SABE and GRAR WGS data to the human reference genome

hg38 with DRAGEN-GATK (Illumina, version 3.6.4 or superior) and genotyped using Illumina's

DRAGEN DNA pipeline as previously described <sup>4,5</sup>. Of 313 BC-related SNPs, 308 were present

in all cohorts and used for downstream analyses. We call this set 313-SNPs for ease of

reading.

Ancestry, LD, PRS, and modeling. We inferred global ancestry for all cohorts using Principal

Component Analysis (PCA) and supervised ADMIXTURE 15. We used 1000 Genomes Project

Phase 3 (1KGP3) individuals classified as African (AFR), European (EUR) and East Asian

(EAS) for ancestry-specific PRS distributions comparisons (see Supplementary Methods).

We collected overlapping variants in all sets of individuals within a region of 500 kbp upstream

and downstream of the 313-PRS and used varLD<sup>16</sup> to perform LD comparisons between SABE

and GRAR, as well as with 1KGP3 individuals grouped according to the three main continental

ancestries (AFR, EUR, EAS).

We calculated the 313-PRS separately for all cohorts and 1000KGP3 populations, including

both unaffected and affected women from SABE, GRAR, and the UKBB. Each individual's

PRS was calculated as the sum of the risk alleles dosage, G, times its effect-size (w) for every

variant (i) (PRS =  $\sum_i w_i G_i$ ), using previously inferred weights from an EA- cohort<sup>11</sup>.

To evaluate the PRS regression models performance in the Brazilian and UKBB cohorts we

calculated area under receiver operator curve (AUROC), odds-ratio per standard deviation

(ORperSD) and Partial-R<sup>2</sup> between models with and without the PRS. Confidence intervals

were calculated using 1,000 bootstraps. Scripts to replicate these analyses are available at:

https://github.com/Varstation/313prs-bc-grar-sabe

RESULTS

Since the two Brazilian cohorts were sampled differently, we explored in a comparative way

variables that are known to affect PRS transferability across cohorts: global ancestry

composition, 313-PRS risk allele frequency (RAF), and LD patterns in genomic regions linked

to risk variants.

Patterns of global ancestry inferred both by PCA (Figure 1A) and supervised ADMIXTURE

(Supplementary Figure 1) show that GRAR and SABE share similar ancestry patterns, with

most individuals distributed as a continuum between AFR and EUR ancestries and a small

number of individuals with higher proportions of EAS ancestry. Additionally, both cohorts share

similar patterns of genome-wide principal components (Supplementary Figure 2).

GRAR and SABE have similar RAFs for the BC 313-SNPs (Figure 1B), and both cohorts have

an overall higher correlation with RAFs calculated for the EA subset of 1KGP3 individuals

(Figure 1C) than with the AFR or EAS ancestry subsets (Pearson's cor >= 0.95 in both

comparisons). Both cohorts share the same correlation with the EUR 1KGP3 subset (cor =

0.80), whereas GRAR has a higher RAF correlation with AFR than SABE (cor=0.84 and

cor=0.78, respectively). LD patterns surrounding the 313 risk SNPs are more similar between

5

SABE and GRAR than any of the other pairwise comparisons (Figure 1D).




Figure 1. Allelic frequency and LD patterns for two Brazilian cohorts (SABE and GRAR) (A) Principal component (PC) analysis of GRAR (left) and SABE (right). Plots show PC1 and PC2 in the x-and y-axis, respectively. Different colors refer to 1KGP3 ancestry-specific subsets of individuals. (B) Risk allele frequency (RAF) for GRAR (x-axis) and SABE (y-axis); r, Pearson's correlation coefficient. (C) RAF correlation between Brazilian cohorts and 1KGP3-EUR, -AFR, -EAS (from left to right). GRAR (top row); SABE (bottom row); r, (Pearson's correlation coefficient). 1KGP3. (D) Raw varLD scores for 1Mbp windows centered across the 313-PRS BC risk SNPs. Lines show varLD calculated between SABE and 1KGP3-EUR; 1KGP3-AFR; 1KGP3-EAS; GRAR (dark blue).; x-axis, 0 represents the risk SNP coordinate. In panels A, C, D, AFR (red), EUR (green), and EAS (orange) refer to the African, European, and East Asian subsets of individuals from the 1,000 Genomes Phase 3 (1KGP3).

Prior to PRS analyses, we explored potential effects of different demographic characteristics between the cohorts (Supplementary Table 1). Because the SABE cohort has a small number

of cases (n=21), we simulated sampling and case-control balances of SABE with bootstrap

analyses on UKBB (Supplementary Figure 3) and did not observe bias regarding the small

case numbers present in SABE data.

Next, we calculated 313-PRS for GRAR, SABE, GRAR+SABE (G+S) and UKBB cohorts. We

compared the 313-PRS PRS distribution obtained from all individuals in GRAR (n=853), SABE

(n=753) and UKBB (n=264,307). The Brazilian cohorts and non-European ancestry 1KGP3

populations - AFR (n=258) and EAS (n=260) - had a distribution of 313-PRS values shifted

towards higher values than the UKBB and EUR-1KGP3 (n=263), which had similar

distributions (Wilcoxon sum rank test, p = 0.69) between them and statistically significant

differences from all other cohorts ( $p \le 0.0001$  for all comparisons (Figure 2A).

In both Brazilian cohorts, the mean 313-PRS was significantly higher in cases than controls

(Wilcoxon rank sum test, GRAR: p < 0.0001, SABE: p = 0.012). When we performed a Z-

score normalization using the UKBB mean and standard deviation (SD) we found that the third

quartiles of SABE and GRAR surpassed the top 10% UKBB PRS (Figure 2B), suggesting that

PRS assessment without the specific population mean and sd will inflate the number of

individuals inferred to be in higher risk categories.

SABE had a wider range of odds-ratio (OR) values while G+S, GRAR and UKBB share scales

of OR values (up to OR~2) distributed along PRS quantile bins (Figure 2C). In all cohorts, the

comparison of OR between quantiles showed that higher PRS quantiles are associated with

higher BC OR.

We found similar PRS predictive power for GRAR, G+S, and UKBB cohorts, considering

AUROC (only 313-PRS). Whereas SABE showed a higher AUROC (Figure 2D) it has a lower

predictive power according the Partial-R<sup>2</sup> metrics (full model including age+5PCs compared to

7

model without 313-PRS) with bootstrap analysis (Supplementary Figure 4). It is important to

note that SABE cohort is on average older (72 yrs vs. 40 yrs) and less affected than the GRAR

cohort (2.8% cases vs. 38% cases) and the potential effects of these differences could contribute to the results.




Figure 2. Overall PRS distribution and model assessment. (A) 313-PRS distributions for SABE, GRAR, UKBB, and three subsets from the 1KGP3 (AFR, EUR, EAS). (B) Normalized 313-PRS based on G+S (on the left) and UKBB (on the right). The black line represents the top 10% UKBB-PRS threshold. (C) Odds-ratios based on 313-PRS values for SABE, GRAR, SABE and GRAR combined (G+S), and UKBB. (D) Receiver-operator curves (ROC) of the predictive power of a logistic regression model with 313-PRS as the sole predictor of breast cancer. Numbers in the figure indicate the AUROC and values in parenthesis are the 95% confidence intervals.

**DISCUSSION** 

We observed that the BC 313-PRS values were on average higher in the two Brazilian cohorts

and non-European ancestry groups from the 1KGP3 compared to the UKBB and 1KGP3-EUR.

Similar findings have been reported in other BC PRS and specifically for the BC 313-PRS.

One study assessed the transferability of a standardized 313-PRS <sup>17</sup> to East Asian ancestry

cohorts. The standardization was based on EA values and aimed at enabling comparisons of

the PRS performance across populations. However, the authors concluded that a better

approach is to standardize the 313-PRS to Asian ancestry values instead, thus minimizing

overfitting. We performed a similar approach, by standardizing the 313-PRS to both the EA

and Brazilian distributions. We find that, indeed, the former would lead to an inflated number

of individuals placed in the high risk groups compared to the latter.

Fritsche and colleagues constructed a BC PRS specifically for the EA subset of UKBB

individuals using a sparse set of 334 SNPs (similar to our approach) and a different approach

leveraging the weight of 1.1 million SNPs based on population-specific LD patterns for the

score and tested both PRSs in UKBB individuals from Asian and African ancestry groups. They

observed different distributions in group means of tested BC PRS across European, South

Asian, African and East Asian ancestry groups. Their BC-PRS for both PRS approaches were

on average higher in non-EUR groups, which we also describe here, but the PRS distribution

was nevertheless right-shifted in cases compared to controls and associated with increased

continuous ORs when standardized to one SD within each ancestry group <sup>18</sup>.

Our classification performance was moderate (AUROC=0.60), with an increasing proportion of

cases in the top 20% percentile of the 313-PRS distributions in both Brazilian cohorts. A study

using the eMERGE network <sup>19</sup> to assess the transferability of BC PRS models, including the

313-PRS, compared cohorts with a predominance of EA ancestry to cohorts including women

with African and also various proportions of admixed European-African ancestry and self-

identified (e.g. not based on genomic ancestry) Latinx women. The AUROCs in self-identified

Latinx women for different BC PRS ranged from 0.53 to 0.56 <sup>19</sup>, compared to 0.63 for the EA

cohort. An increasing number of other studies, as well as our own observations, highlight the

need to improve the representation of diverse population groups in genomic research cohorts

so that population-specific effect sizes can improve PRS prediction power.

Our study has limitations inherent to a general paucity of genomic-level datasets that also

include phenotypic data. SABE and GRAR were sampled with different designs and thus they

differ in at least two important aspects. The median age of SABE (72 years) is higher than the

BC median age of onset (61.8 years) <sup>20</sup> and higher than the median age in GRAR (40 years)

and the UKBB (58 years). Thus, a survival effect is likely to play a role in differences seen

between these cohorts. In fact, unaffected elderly can be considered super-controls, meaning

that at a given statistical power, less individuals are required to obtain equivalent effect sizes

in case-control setups <sup>21</sup>. Moreover, the restricted number of cases may affect the results due

to low sampling power.

Our findings showed that combining GRAR and SABE led to a loss of predictive power. We

interpret this as being due to the important differences highlighted above (age, recruitment

approach, family history) and different proportions of cases and controls given that, as shown

here, their patterns of LD and RAF are remarkably similar. If large-scale cohorts such as GRAR

and SABE are planned and designed in an integrated way, such discrepancies would likely be

reduced. On the other hand, our findings also highlight how much the performance metric

depends on the sample (cohort), even when ancestry profiles are similar, as highlighted by

others.

Our study ultimately provides insights of extreme samples, which may not reflect the expected

ancestry-driven reduction in PRS transferability. Given the absence of a valuable large

Brazilian population-based biobank, the approach of using available samples with targeted

design is an alternative to test PRS transferability. With these important caveats in mind, we

note that neither age nor family history (GRAR cases inclusion criterium) are correlated with

ancestry components in those cohorts and, as we showed here, the ancestry profiles are

remarkably similar.

A reduced PRS predictive power compared to the population or ancestry group from the

original is expected due to differences in ancestry composition, allele frequencies and LD

patterns across populations. Although both target samples are Brazilian, it is important to

consider that the GRAR and SABE cohorts were collected for different purposes and from

regions with different demographic histories. Even with different backgrounds both cohorts

bear a Brazilian signature being closer to each other than with any other ancestry, suggesting

the results could be observed in other Brazilian admixed cohorts. Additional validation on these

findings, in particular in correctly ascertaining cases within the highest PRS percentiles, might

advocate towards clinical applications on transferred PRS, while large GWAS on each

ancestral groups are performed and crucial non-European population-based biobanks are

constructed.

**ACKNOWLEDGMENTS AND FUNDING** 

This research has been conducted using the UK Biobank Resource under Application Number

74348. Funding for Michel Naslavsky, Mayana Zatz and Yeda Duarte at University of São

Paulo was provided by grants and fellowships from São Paulo Research Foundation

(FAPESP) (CEPID 2013/08028-1, SABE 2014/50649-6, INCT 2014/50931-3), and Conselho

Nacional de Desenvolvimento Científico e Tecnológico - CNPq (INCT 465355/2014-5).

Funding for Helena Brentani and Catarina S. Gomes at University of São Paulo was provided

by grants and fellowships from FAPESP (grant #2020/16376-3 and #2018/18560-6), and the

Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brasil (CNPq) grant #310823/2021-8. We thank Varsomics team for support and infrastructure for data processing

(https://varsomics.com/). This research was made possible through access to the data and

findings generated by the Rare Genomes Project. The Rare Genomes Project is an initiative of

Hospital Israelita Albert Einstein in partnership with the Programa de Apoio ao

Desenvolvimento Institucional do Sistema Único de Saúde (PROADI-SUS) from the Brazilian

11

Ministry of Health.

Also, we would like to thank the engineering support of Patrícia Campos, Cassio Reginato and Bruno Laget Merino, and the administrative support of Maura Farias.

## **REFERENCES**

- 1. Mars N, Kerminen S, Feng YCA, et al. Genome-wide risk prediction of common diseases across ancestries in one million people. *Cell Genom*. 2022;2(4):100118. doi:10.1016/j.xgen.2022.100118
- Privé F, Arbel J, Vilhjálmsson BJ. LDpred2: better, faster, stronger. *Bioinformatics*.
   2020;36(22-23):btaa1029-.
   doi:10.1093/bioinformatics/btaa1029
- 3. Bitarello BD, Mathieson I. Polygenic Scores for Height in Admixed Populations. *G3*Bethesda Md. 2020;10(11):4027-4036. doi:10.1534/g3.120.401658
- Coelho AVC, Mascaro-Cordeiro B, Lucon DR, et al. The Brazilian Rare Genomes Project:
   Validation of Whole Genome Sequencing for Rare Diseases Diagnosis. *Frontiers Mol Biosci*.
   2022;9:821582.
   doi:10.3389/fmolb.2022.821582
- 5. Naslavsky MS, Scliar MO, Yamamoto GL, et al. Whole-genome sequencing of 1,171 elderly admixed individuals from Brazil. *Nat Commun.* 2022;13(1):1004. doi:10.1038/s41467-022-28648-3
- 6. Ruan Y, Lin YF, Feng YCA, et al. Improving polygenic prediction in ancestrally diverse populations. *Nat Genet*. 2022;54(5):573-580. doi:10.1038/s41588-022-01054-7
- 7. Marnetto D, Pärna K, Läll K, et al. Ancestry deconvolution and partial polygenic score can improve susceptibility predictions in recently admixed individuals. Nat Commun. 2020;11(1):1628.

  doi:10.1038/s41467-020-15464-w
- 8. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019;51(4):584-591. doi:10.1038/s41588-019-0379-x
- 9. Zhang H, Ahearn TU, Lecarpentier J, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572-581. doi:10.1038/s41588-020-0609-2
- 10. Du Z, Gao G, Adedokun B, et al. Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. *Jnci J National Cancer Inst.* 2021;113(9):1168-1176.

doi:10.1093/jnci/djab050

- 11. Mavaddat N, Michailidou K, Dennis J, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genetics*. 2019;104(1):21-34. doi:10.1016/j.ajhg.2018.11.002
- 12. Hurson AN, Choudhury PP, Gao C, et al. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *Int J Epidemiol.* 2021;50(6):1897-1911. doi:10.1093/ije/dyab036
- 13. Choudhury PP, Brook MN, Hurson AN, et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. *Breast Cancer Res*Bcr. 2021;23(1):22. doi:10.1186/s13058-021-01399-7
- 14. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *Plos Med.* 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 15. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. *Genome Res.* 2009;19(9):1655-1664. doi:10.1101/gr.094052.109
- 16. Ong RTH, Teo YY. varLD: a program for quantifying variation in linkage disequilibrium patterns between populations. Bioinformatics. 2010;26(9):1269-1270. doi:10.1093/bioinformatics/btq125
- 17. Ho WK, Tan MM, Mavaddat N, et al. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun. 2020;11(1):3833. doi:10.1038/s41467-020-17680-w
- 18. Fritsche LG, Ma Y, Zhang D, et al. On cross-ancestry cancer polygenic risk scores. *Plos Genet*. 2021;17(9):e1009670. doi:10.1371/journal.pgen.1009670
- 19. Liu C, Zeinomar N, Chung WK, et al. Generalizability of Polygenic Risk Scores for Breast Cancer Among Women With European, African, and Latinx Ancestry. *Jama Netw Open*. 2021;4(8):e2119084. doi:10.1001/jamanetworkopen.2021.19084
- 20. Bidoli E, Virdone S, Hamdi-Cherif M, et al. Worldwide Age at Onset of Female Breast

Cancer: A 25-Year Population-Based Cancer Registry Study. Sci Rep-uk. 2019;9(1):14111. doi:10.1038/s41598-019-50680-5

21. Pinese M, Lacaze P, Rath EM, et al. The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat Commun. 2020;11(1):435. doi:10.1038/s41467-019-14079-0